Receptors, endocytosis, and trafficking: The biological basis of targeted delivery of antisense and siRNA oligonucleotides

Journal of Drug Targeting

Volumn 21, Issue 1, 2013, Pages 27-43

  Juliano, R L ^a   Carver, K ^a   Cao, C ^a   Ming, X ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Antisense; Delivery; Endocytosis; Oligonucleotides; Receptors; SiRNA; Trafficking

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTEGRIN; LIPOPROTEIN RECEPTOR; RECEPTOR; SMALL INTERFERING RNA; TIROFIBAN; TYROSINE KINASE RECEPTOR;

BINDING AFFINITY; CELL MIGRATION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HEART; INTERNALIZATION; KIDNEY; LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; CELL NUCLEUS; CYTOSOL; ENDOCYTOSIS; HUMANS; INTEGRINS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; RNA; RNA, SMALL INTERFERING;

EID: 84872038857     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.740674     Document Type: Review

References (159)

1. Akhtar S. (2010). Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Expert Opin Drug Metab Toxicol, 6, 1347-1362.
2. Alam MR, Dixit V, Kang H, Li ZB, Chen X, Trejo J, Fisher M, Juliano RL. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res, 36, 2764-2776.
3. Alam MR, Ming X, Dixit V, Fisher M, Chen X, Juliano RL. (2010). The biological efect of an antisense oligonucleotide depends on its route of endocytosis and trafcking. Oligonucleotides, 20, 103-109.
4. Alam MR, Ming X, Fisher M, Lackey JG, Rajeev KG, Manoharan M, Juliano RL. (2011). Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem, 22, 1673-1681.
5. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
6. Angers CG, Merz AJ. (2011). New links between vesicle coats and Rab-mediated vesicle targeting. Semin Cell Dev Biol, 22, 18-26.
7. Aplin AE, Stewart SA, Assoian RK, Juliano RL. (2001). Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol, 153, 273-282.
8. Armbruster BN, Roth BL. (2005). Mining the receptorome. J Biol Chem, 280, 5129-5132.
9. Avraamides CJ, Garmy-Susini B, Varner JA. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer, 8, 604-617.
10. Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J. (1994). Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol, 14, 5192-5201.
11. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, Meijer DK, Poelstra K. (1999). Albumin modifed with mannose 6-phosphate: A potential carrier for selective delivery of antifbrotic drugs to rat and human hepatic stellate cells. Hepatology, 29, 1486-1493.
12. Bennett CF, Swayze EE. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol, 50, 259-293.
13. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. (2004). Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176, 117-123.
14. Bretscher MS. (1992). Circulating integrins: α 5 β 1, α 6 β 4 and Mac-1, but not α 3 β 1, α 4 β 1 or LFA-1. EMBO J, 11, 405-410.
15. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. (2009). Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res, 15, 3244-3250.
16. Brown MS, Goldstein JL. (1985). The receptor model for transport of cholesterol in plasma. Ann N Y Acad Sci, 454, 178-182.
17. Burnett JC, Rossi JJ. (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol, 19, 60-71.
18. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, Tarone G, Deflippi P. (2004). Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans, 32, 438-442.
19. Cabrera-Vera TM, Vanhauwe J, Tomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. (2003). Insights into G protein structure, function, and regulation. Endocr Rev, 24, 765-781.
20. Calebiro D, Nikolaev VO, Persani L, Lohse MJ. (2010). Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci, 31, 221-228.
21. Caswell PT, Chan M, Lindsay AJ, McCafrey MW, Boettiger D, Norman JC. (2008). Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol, 183, 143-155.
22. Caswell PT, Vadrevu S, Norman JC. (2009). Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol, 10, 843-853.
23. Chang L, Karin M. (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
24. Chen X. (2006). Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem, 6, 227-234.
25. Ciardiello F, Tortora G. (2008). EGFR antagonists in cancer treatment. N Engl J Med, 358, 1160-1174.
26. Cornelio DB, Roesler R, Schwartsmann G. (2007). Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol, 18, 1457-1466.
27. Desgrosellier JS, Cheresh DA. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 10, 9-22.
28. Doherty GJ, McMahon HT. (2009). Mechanisms of endocytosis. Annu Rev Biochem, 78, 857-902.
29. Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ. (2010). Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev, 62, 1344-1357.
30. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
31. Drake MT, Shenoy SK, Lefkowitz RJ. (2006). Trafcking of G protein-coupled receptors. Circ Res, 99, 570-582.
32. Duncan MC, Ho DG, Huang J, Jung ME, Payne GS. (2007). Composite synthetic lethal identifcation of membrane trafc inhibitors. Proc Natl Acad Sci USA, 104, 6235-6240.
33. Edin ML, Juliano RL. (2005). Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor. Mol Cell Biol, 25, 4466-4475.
34. Feng Y, Press B, Wandinger-Ness A. (1995). Rab 7: an important regulator of late endocytic membrane trafc. J Cell Biol, 131, 1435-1452.
35. Filmore D. (2004). Its a GPCR world. Mod Drug Discov, 7, 24-28.
36. Garcia-Bennett A, Nees M, Fadeel B. (2011). In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol, 81, 976-984.
37. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hofman TJ. (2007). In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med, 48, 1327-1337.
38. Giebing G, Tölle M, Jürgensen J, Eichhorst J, Furkert J, Beyermann M, Neuschäfer-Rube F, Rosenthal W, Zidek W, van der Giet M, Oksche A. (2005). Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res, 97, 707-715.
39. Gilman AG. (1995). Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci Rep, 15, 65-97.
40. Glebov OO, Bright NA, Nichols BJ. (2006). Flotillin-1 defnes a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol, 8, 46-54.
41. Goh LK, Huang F, Kim W, Gygi S, Sorkin A. (2010). Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol, 189, 871-883.
42. Grosshans BL, Ortiz D, Novick P. (2006). Rabs and their efectors: achieving specifcity in membrane trafc. Proc Natl Acad Sci USA, 103, 11821-11827.
43. Gschwind A, Fischer OM, Ullrich A. (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 4, 361-370.
44. Gu Z, Noss EH, Hsu VW, Brenner MB. (2011). Integrins trafc rapidly via circular dorsal rufes and macropinocytosis during stimulated cell migration. J Cell Biol, 193, 61-70.
45. Guo W, Giancotti FG. (2004). Integrin signalling during tumour progression. Nat Rev Mol Cell Biol, 5, 816-826.
46. Hanyaloglu AC, von Zastrow M. (2008). Regulation of GPCRs by endocytic membrane trafcking and its potential implications. Annu Rev Pharmacol Toxicol, 48, 537-568.
47. Hernandez-Gea V, Friedman SL. (2011). Pathogenesis of liver fbrosis. Annu Rev Pathol, 6, 425-456.
48. Hopkins AL, Groom CR. (2002). The druggable genome. Nat Rev Drug Discov, 1, 727-730.
49. Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. (2006). [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3, '5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantifcation of native P2Y1 receptors. Br J Pharmacol, 147, 459-467.
50. Howes MT, Mayor S, Parton RG. (2010). Molecules, mechanisms, and cellular roles of clathrin-independent endocytosis. Curr Opin Cell Biol, 22, 519-527.
51. Humphries JD, Byron A, Humphries MJ. (2006). Integrin ligands at a glance. J Cell Sci, 119, 3901-3903.
52. Huotari J, Helenius A. (2011). Endosome maturation. EMBO J, 30, 3481-3500.
53. Huveneers S, Danen EH. (2009). Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci, 122, 1059-1069.
54. Hwang JY, Park J, Kang BJ, Lubow DJ, Chu D, Farkas DL, Shung KK, Medina-Kauwe LK. (2012). Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles. PLoS ONE, 7, e34463.
55. Hynes RO. (2002a). Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-687.
56. Hynes RO. (2002b). A reevaluation of integrins as regulators of angiogenesis. Nat Med, 8, 918-921.
57. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-354.
58. Imai Y, Leung CK, Friesen HG, Shiu R P. (1982). Epidermal growth factor receptors and efect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. Cancer Res, 42, 4394-4398.
59. Jackson DY. (2002). α 4 integrin antagonists. Curr Pharm Des, 8, 1229-1253.
60. Juliano RL. (2002). Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol, 42, 283-323.
61. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A. (2004). Integrin regulation of cell signalling and motility. Biochem Soc Trans, 32, 443-446.
62. Juliano R, Bauman J, Kang H, Ming X. (2009). Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm, 6, 686-695.
63. Juliano RL, Ming X, Nakagawa O, Xu R, Yoo H. (2011). Integrin targeted delivery of gene therapeutics. Teranostics, 1, 211-219.
64. Juliano RL, Ming X, Nakagawa O. (2012a). Cellular uptake and intracellular trafcking of antisense and siRNA oligonucleotides. Bioconjug Chem, 23, 147-157.
65. Juliano RL, Ming X, Nakagawa O. (2012b). The chemistry and biology of oligonucleotide conjugates. Acc Chem Res, 45, 1067-1076.
66. Karjalainen M, Kakkonen E, Upla P, Paloranta H, Kankaanpää P, Liberali P, Renkema GH, Hyypiä T, Heino J, Marjomäki V. (2008). A Raft-derived, Pak1-regulated entry participates in α2β1 integrin-dependent sorting to caveosomes. Mol Biol Cell, 19, 2857-2869.
67. Kermorgant S, Parker PJ. (2008). Receptor trafcking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol, 182, 855-863.
68. Kerr MC, Teasdale RD. (2009). Defning macropinocytosis. Trafc, 10, 364-371.
69. Khorev O, Stokmaier D, Schwardt O, Cutting B, Ernst B. (2008). Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem, 16, 5216-5231.
70. Kim C, Ye F, Ginsberg MH. (2011). Regulation of integrin activation. Annu Rev Cell Dev Biol, 27, 321-345.
71. Kimple AJ, Bosch DE, Giguère PM, Siderovski DP. (2011). Regulators of G-protein signaling and their Ga substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev, 63, 728-749.
72. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, 6732-6740.
73. Koch S, Claesson-Welsh L. (2012). Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med, 2, a006502.
74. Kornberg LJ, Earp HS, Turner CE, Prockop C, Juliano RL. (1991). Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of β 1 integrins. Proc Natl Acad Sci USA, 88, 8392-8396.
75. Krause DS, Van Etten RA. (2005). Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353, 172-187.
76. Kristensen SD, Grove EL, Hvas AM. (2012). P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients? Tromb Haemost, 108, 203-205.
77. Kunz S. (2009). Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology, 387, 245-249.
78. Lajoie P, Nabi IR. (2010). Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol, 282, 135-163.
79. Lazzara MJ, Laufenburger DA. (2009). Quantitative modeling perspectives on the ErbB system of cell regulatory processes. Exp Cell Res, 315, 717-725.
80. Lemmon MA, Schlessinger J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141, 1117-1134.
81. Levitzki A, Atlas D, Steer ML. (1974). The binding characteristics and number of β-adrenergic receptors on the turkey erythrocyte. Proc Natl Acad Sci USA, 71, 2773-2776.
82. Li S, Huang S, Peng SB. (2005). Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol, 27, 1329-1339.
83. Lin TH, Chen Q, Howe A, Juliano RL. (1997). Cell anchorage permits efcient signal transduction between ras and its downstream kinases. J Biol Chem, 272, 8849-8852.
84. Liu X, Wang Y, Hnatowich DJ. (2011). A nanoparticle for tumor targeted delivery of oligomers. Methods Mol Biol, 764, 91-105.
85. Lobert VH, Brech A, Pedersen NM, Wesche J, Oppelt A, Malerød L, Stenmark H. (2010). Ubiquitination of α 5 β 1 integrin controls fbroblast migration through lysosomal degradation of fbronectin-integrin complexes. Dev Cell, 19, 148-159.
86. Low PS, Kularatne SA. (2009). Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol, 13, 256-262.
87. Mai A, Veltel S, Pellinen T, Padzik A, Cofey E, Marjomäki V, Ivaska J. (2011). Competitive binding of Rab21 and p120RasGAP to integrins regulates receptor trafc and migration. J Cell Biol, 194, 291-306.
88. Mainou BA, Dermody TS. (2012). Transport to late endosomes is required for efcient reovirus infection. J Virol, 86, 8346-8358.
89. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. (2011). Mechanisms of integrin activation and trafcking. Curr Opin Cell Biol, 23, 607-614.
90. Miaczynska M, Bar-Sagi D. (2010). Signaling endosomes: seeing is believing. Curr Opin Cell Biol, 22, 535-540.
91. Millard M, Odde S, Neamati N. (2011). Integrin targeted therapeutics. Teranostics, 1, 154-188.
92. Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL. (2010). Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res, 38, 6567-6576.
93. Ming X, Sato K, Juliano RL. (2011). Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release, 153, 83-92.
94. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Tompson JD, Kalinski H, Skaliter R, Erlich S, Feinstein E. (2009). siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol, 20, 1754-1764.
95. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. (2007). Integrins and cancer. Oncology (Williston Park), 21, 13-20.
96. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA. (2006). Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ter, 5, 3122-3129.
97. Munger JS, Sheppard D. (2011). Cross talk among TGF-ß signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol, 3, a005017.
98. Nakagawa O, Ming X, Huang L, Juliano RL. (2010). Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc, 132, 8848-8849.
99. Napione L, Pavan S, Veglio A, Picco A, Bofetta G, Celani A, Seano G, Primo L, Gamba A, Bussolino F. (2012). Unraveling the infuence of endothelial cell density on VEGF-A signaling. Blood, 119, 5599-5607.
100. Natarajan K, Berk BC. (2006). Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol, 332, 51-77.
101. Nguyen J, Szoka FC. (2012). Nucleic acid delivery: the missing pieces of the puzzle? Acc Chem Res, 45, 1153-1162.
102. Niu G, Chen X. (2011). Why integrin as a primary target for imaging and therapy. Teranostics, 1, 30-47.
103. Parachoniak CA, Park M. (2012). Dynamics of receptor trafcking in tumorigenicity. Trends Cell Biol, 22, 231-240.
104. Parsons JT. (2003). Focal adhesion kinase: the frst ten years. J Cell Sci, 116, 1409-1416.
105. Pfefer SR. (2011). Entry at the trans-face of the Golgi. Cold Spring Harb Perspect Biol, 3. DOI: 10.1101/cshperspect.a005272
106. Pierschbacher MD, Ruoslahti E. (1984). Cell attachment activity of fbronectin can be duplicated by small synthetic fragments of the molecule. Nature, 309, 30-33.
107. Poelstra K, Prakash J, Beljaars L. (2012). Drug targeting to the diseased liver. J Control Release, 161, 188-197.
108. Post SR, Hilal-Dandan R, Urasawa K, Brunton LL, Insel PA. (1995). Quantifcation of signalling components and amplifcation in the β-adrenergic-receptor-adenylate cyclase pathway in isolated adult rat ventricular myocytes. Biochem J, 311, 75-80.
109. Proulx CD, Simaan M, Escher E, Laporte SA, Guillemette G, Leduc R. (2005). Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization. Biochem J, 385, 115-123.
110. Pyne NJ, Pyne S. (2011). Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? Trends Pharmacol Sci, 32, 443-450.
111. Rangamani P, Iyengar R. (2008). Modelling cellular signalling systems. Essays Biochem, 45, 83-94.
112. Ross B, McKendy K, Giaid A. (2010). Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol, 298, R1156-R1172.
113. Rozema DB, Lewis DL, Wakefeld DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE, Wolf JA. (2007). Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA, 104, 12982-12987.
114. Sáenz JB, Sun WJ, Chang JW, Li J, Bursulaya B, Gray NS, Haslam DB. (2009). Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nat Chem Biol, 5, 157-165.
115. Salazar NC, Chen J, Rockman HA. (2007). Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta, 1768, 1006-1018.
116. Saperstein LA, Jirtle RL, Farouk M, Tompson HJ, Chung KS, Meyers WC. (1994). Transforming growth factor-β 1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fbrosis in the rat. Hepatology, 19, 412-417.
117. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y. (2008). Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specifc chaperone. Nat Biotechnol, 26, 431-442.
118. Savage B, Marzec UM, Chao BH, Harker LA, Maraganore JM, Ruggeri ZM. (1990). Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function. J Biol Chem, 265, 11766-11772.
119. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. (1992). pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA, 89, 5192-5196.
120. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med, 267, 9-21.
121. Schwartz SL, Cao C, Pylypenko O, Rak A, Wandinger-Ness A. (2007). Rab GTPases at a glance. J Cell Sci, 120, 3905-3910.
122. Schwartz MA. (2010). Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb Perspect Biol, 2, a005066.
123. Sczekan MM, Juliano RL. (1990). Internalization of the fbronectin receptor is a constitutive process. J Cell Physiol, 142, 574-580.
124. Senoo H, Yoshikawa K, Morii M, Miura M, Imai K, Mezaki Y. (2010). Hepatic stellate cell (vitamin A-storing cell) and its relative-past, present and future. Cell Biol Int, 34, 1247-1272.
125. Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC. (2008). Herceptin. Handb Exp Pharmacol, 183-219.
126. Shimaoka M, Springer TA. (2003). Terapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov, 2, 703-716.
127. Shimizu H, Hori Y, Kaname S, Yamada K, Nishiyama N, Matsumoto S, Miyata K, Oba M, Yamada A, Kataoka K, Fujita T. (2010). siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol, 21, 622-633.
128. Shukla AK, Xiao K, Lefkowitz RJ. (2011). Emerging paradigms of ß-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci, 36, 457-469.
129. Singh S, Narang AS, Mahato RI. (2011). Subcellular fate and of-target efects of siRNA, shRNA, and miRNA. Pharm Res, 28, 2996-3015.
130. Sioud M. (2009). Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol, 487, 41-59.
131. Soh UJ, Dores MR, Chen B, Trejo J. (2010). Signal transduction by protease-activated receptors. Br J Pharmacol, 160, 191-203.
132. Sorkin A, Goh LK. (2008). Endocytosis and intracellular trafcking of ErbBs. Exp Cell Res, 314, 3093-3106.
133. Sorkin A, von Zastrow M. (2009). Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol, 10, 609-622.
134. Stechmann B, Bai SK, Gobbo E, Lopez R, Merer G, Pinchard S, Panigai L, Tenza D, Raposo G, Beaumelle B, Sauvaire D, Gillet D, Johannes L, Barbier J. (2010). Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell, 141, 231-242.
135. Stenmark H, Parton RG, Steele-Mortimer O, Lütcke A, Gruenberg J, Zerial M. (1994). Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J, 13, 1287-1296.
136. Stenmark H. (2009). Rab GTPases as coordinators of vesicle trafc. Nat Rev Mol Cell Biol, 10, 513-525.
137. Stockert RJ. (1995). The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev, 75, 591-609.
138. Streuli CH, Akhtar N. (2009). Signal co-operation between integrins and other receptor systems. Biochem J, 418, 491-506.
139. Sugo T, Mori M. (2008). Another ligand fshing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain. Peptides, 29, 809-812.
140. Szabo AM, Howell NR, Pellegrini P, Greguric I, Katsifs A. (2012). Development and validation of competition binding assays for afnity to the extracellular matrix receptors, a(v)β(3) and a(IIb) β(3) integrin. Anal Biochem, 423, 70-77.
141. Tohidkia MR, Barar J, Asadi F, Omidi Y. (2012). Molecular considerations for development of phage antibody libraries. J Drug Target, 20, 195-208.
142. Tzanidis A, Hannan RD, Tomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. (2003). Direct actions of urotensin II on the heart: implications for cardiac fbrosis and hypertrophy. Circ Res, 93, 246-253.
143. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J. (2010). A status report on RNAi therapeutics. Silence, 1, 14.
144. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos, 34, 1393-1397.
145. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. (2011). Targeting Axl and Mer kinases in cancer. Mol Cancer Ter, 10, 1763-1773.
146. von Kleist L, Haucke V. (2011). At the Crossroads of Chemistry and Cell Biology: Inhibiting Membrane Trafc by Small Molecules. Trafc. DOI: 10.1111/j.1600-0854.2011.01292.x
147. Wax MB, Molinof PB. (1987). Distribution and properties of β-adrenergic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci, 28, 420-430.
148. Wickström SA, Fässler R. (2011). Regulation of membrane trafc by integrin signaling. Trends Cell Biol, 21, 266-273.
149. Wolfe BL, Trejo J. (2007). Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Trafc, 8, 462-470.
150. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stofel M. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol, 25, 1149-1157.
151. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. (2001). Crystal structure of the extracellular segment of integrin α Vβ3. Science, 294, 339-345.
152. Yamada T, Peng CG, Matsuda S, Addepalli H, Jayaprakash KN, Alam MR, Mills K, Maier MA, Charisse K, Sekine M, Manoharan M, Rajeev KG. (2011). Versatile site-specifc conjugation of small molecules to siRNA using click chemistry. J Org Chem, 76, 1198-1211.
153. Yoshimoto T, Matsushita M, Hirata Y. (2004). Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides, 25, 1775-1781.
154. Zelensky AN, Gready JE. (2005). The C-type lectin-like domain superfamily. FEBS J, 272, 6179-6217.
155. Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, Kubo N, Wong A, Min LR, Budohn ME, Garcia B, Jevnikar AM, Min W P. (2008). Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol, 173, 973-980.
156. Zhu Z, Witte L. (1999). Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs, 17, 195-212.
157. Zhu YC, Zhu YZ, Moore PK. (2006). The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol, 148, 884-901.
158. Zhu L, Mahato RI. (2010). Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem, 21, 2119-2127.
159. Zwang Y, Yarden Y. (2009). Systems biology of growth factor-induced receptor endocytosis. Trafc, 10, 349-363.